The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis.

ABSTRACT:

Background & aims

With a drastic increase in the number of chronic hepatitis B (CHB) patients with coexisting nonalcoholic fatty liver disease (NAFLD), there is an urgent need to evaluate antiviral treatment effects in this special population.

Methods

CHB patients with hepatic steatosis (CHB + HS) were prospectively recruited with followed-up of 3 years. HS and liver fibrosis were assessed by transient elastography. HS was defined as controlled attenuation parameter (CAP) ≥248 dB/m, and fibrosis progression was defined with ≥1-stage fibrosis increment. Multivariate and propensity score matching (PSM) analysis were used to evaluate antiviral therapy effects on fibrosis progression.

Results

In total 212 recruited CHB + HS patients (median age 36 years, median ALT 59 U/L

SUBMITTER: Hu D 

PROVIDER: S-EPMC11000017 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature